You can buy Asciminib at the lowest price at Nextgen.ooo online pharmacy. Asciminib is a tyrosine kinase inhibitor (TKI) used to treat chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein, which drives CML proliferation in most patients with the disease. It has also shown benefit in Ph+ CML with the T315I mutation, which results in a BCR-ABL1 mutant that is generally resistant to treatment compared to wild-type BCR-ABL1. Existing ABL inhibitors compete for the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain (dasatinib, bosutinib) and those that target the inactive kinase domain (imatinib, nilotinib, ponatinib). Asciminib is unique in that it acts as an allosteric inhibitor by binding to the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation.
 
It can be administered orally once or twice daily depending on the condition being treated. By increasing the total daily dose by 5-fold compared to standard therapy (80 mg daily versus 400 mg daily), it can be used to treat Ph+ CML with the T315I mutation, a commonly treatment-resistant variant of the disease.
 
As with many other chemotherapeutic agents, treatment with asciminib may result in various forms of myelosuppression, including thrombocytopenia and neutropenia. Patients should have frequent laboratory monitoring throughout treatment, and dose adjustments may be required based on the severity of the effects observed. Patients may also experience pancreatic and/or cardiovascular toxicity, both of which require frequent monitoring and may require dose adjustments according to the prescribing information.